Every material Form 8-K Mineralys Therapeutics, Inc. has filed with the SEC since October 19, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Mineralys Therapeutics reported a third-quarter 2026 net loss of $57.3 million, up from $36.9 million a year earlier, as general and administrative expenses rose to $37.4 million to prepare for commercial launch of lorundrostat. The company said its FDA review of lorundrostat has a PDUFA target date of December 22, 2026, and that its cash should fund operations into 2028. A director, Derek DiRocco, also plans to resign from the board effective December 31, 2026.
Net loss was $57.3 million, or $0.64 per share, versus $36.9 million, or $0.52 per share, a year earlier.
General and administrative expenses were $37.4 million, up from $9.7 million, driven by $15.4 million in higher professional fees and $11.4 million in higher personnel costs.
Cash, cash equivalents and investments were $624.7 million at September 30, 2026, versus $656.6 million at December 31, 2025.
Director Derek DiRocco will resign from the board effective December 31, 2026, and said the decision was not due to any disagreement with the company.
Mineralys Therapeutics and Tanabe Pharma terminated the License Agreement for lorundrostat on October 27, 2026, and Tanabe assigned the related patents and know-how to Mineralys. Mineralys remains obligated to pay Tanabe the milestone payments under a separate Payment Obligation Agreement, and Tanabe keeps a first-negotiation right for Japan. The filing says the company incurred no material early termination penalties, and the $100.0 million change-of-control payment is no longer tied to the license terms that existed before.
License Agreement terminated and Transferred Intellectual Property assigned to Mineralys on October 27, 2026
Mineralys still owes Tanabe commercial milestone payments of up to $255.0 million plus up to $10.0 million for a potential second indication
Tanabe's right of first negotiation survives for Japan while milestones remain unpaid
No material early termination penalties incurred; full agreements to be filed with the 2026 Form 10-K
Mineralys Therapeutics appointed Kristine Peterson and Lonnel Coats to its Board of Directors effective October 19, 2026, increasing the Board from seven to nine members. The filing says both were granted stock options and restricted stock units under the company's non-employee director compensation program, and the Board determined both are independent under Nasdaq rules.
Kristine Peterson joins as a Class I director (term to 2027 annual meeting) and on the Audit Committee.
Lonnel Coats joins as a Class II director (term to 2028 annual meeting) and on the Compensation Committee.
Each received an option to purchase 16,600 shares and a restricted stock unit award covering 12,400 shares, vesting over three years.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Mineralys Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →